Product Information

LUBIPROSTONE 8 MCG CAPSULE is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.5566 per EA under NDC 00480347906. Its NADAC has been published 196 times since Feb 22, 2023.

FDA first approved this application on Jan 18, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

LUBIPROSTONE 8 MCG CAPSULE

Lubiprostone
$0.5566per EA

Strength

8 ug/1

NDC

00480347906

Classification

Generic

Dosage Form

CAPSULE, GELATIN COATED

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

LUBIPROSTONE

Approval Type

Generic (ANDA)

FDA Application

ANDA209920

FDA Approved

1/18/2022

TE Code

AB

On Market Since

1/3/2023

Pharmacological Classes

Chloride Channel Activator
Chloride Channel Activators

Price Statistics

The NADAC for LUBIPROSTONE 8 MCG CAPSULE has been published 196 times since Feb 22, 2023, and over the history we have for it it has declined 87.2%. The table below summarizes its recorded NADAC range and movement.

Current price$0.5566 per EA
All-time high$4.3426 (Mar 15, 2023)
All-time low$0.5447 (Nov 20, 2024)
52-week high$0.7562
52-week low$0.5493
Median price$0.7628
Average price$1.0712
Largest weekly change-46.8% (Dec 20, 2023)
Weeks tracked196
Tracking sinceFeb 22, 2023

Price History

1W

-1.9%

1M

-1.5%

3M

+1.3%

6M

-22.3%

1Y

-19.7%

3Y

-69.9%

5Y

N/A

All

-87.2%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of LUBIPROSTONE 8 MCG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for LUBIPROSTONE 8 MCG CAPSULE, manufactured by Teva Pharmaceuticals USA Inc., is $0.5566 per EA (NDC 00480347906), effective Nov 18, 2026.

How has the price of LUBIPROSTONE 8 MCG CAPSULE changed over time?

Over the history we have for it, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has declined 87.2%. It has been tracked across 196 weekly CMS publications since Feb 22, 2023.

What are the highest and lowest recorded NADAC prices for LUBIPROSTONE 8 MCG CAPSULE?

Since Feb 22, 2023, the NADAC for LUBIPROSTONE 8 MCG CAPSULE has ranged from a low of $0.5447 (Nov 20, 2024) to a high of $4.3426 (Mar 15, 2023), with a median of $0.7628 per EA.

Are there cheaper alternatives to LUBIPROSTONE 8 MCG CAPSULE?

3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as LUBIPROSTONE 8 MCG CAPSULE in a comparable dosage form, but none are currently priced below it.

Who manufactures LUBIPROSTONE 8 MCG CAPSULE?

LUBIPROSTONE 8 MCG CAPSULE (NDC 00480347906) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.